Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peripheral edema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    109 result(s) found for: Peripheral edema. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2020-005034-15 Sponsor Protocol Number: DXMT Start Date*: 2022-10-05
    Sponsor Name:HOSPITAL DR JOSEP TRUETA
    Full Title: EFFECT OF DEXAMETASONE ON LOWER LIMB EDEMA IN PATIENTS UNDERTAKEN FOR TOTAL HIP ARTHROPLASTY
    Medical condition: POST -OPERATIVE LOWER LIMB EDEMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10014220 Edema extremities LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002790-11 Sponsor Protocol Number: V4.0 Start Date*: 2015-06-08
    Sponsor Name:Ludwig-Maximilians Universität München
    Full Title: Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10054467 Macular edema LLT
    20.0 100000004853 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001761-11 Sponsor Protocol Number: 300488 Start Date*: 2015-08-31
    Sponsor Name:The Department of Cardiothoracic and Vascular Surgery, Aarhus University Hospital
    Full Title: Lymphatic dysfunction as a cause of calcium channel blocker oedema in post-menopausal women
    Medical condition: Calcium channel antagonist induced peripheral edema in post-menopausal women. We hypothesize that this condition is partly due to impaired lymphatic function in these patients.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004867 10067033 Drug side effect LLT
    18.0 100000004867 10034570 Peripheral edema LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004292-40 Sponsor Protocol Number: GODIF Start Date*: 2020-02-17
    Sponsor Name:Department of Anesthesia and Intensive Care Medicine, Nordsjællands hospital
    Full Title: Goal directed fluid removal with furosemide in intensive care patients with fluid overload - A randomised, blinded, placebo-controlled trial (GODIF).
    Medical condition: Treatment of fluid overload in critically ill adult patients in intensive care unit.
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004861 10015766 Extracellular fluid increased LLT
    20.0 100000004861 10016808 Fluid retention in tissues LLT
    24.0 100000004861 10022608 Interstitial fluid increased LLT
    24.1 100000004861 10033303 Overhydration LLT
    20.0 100000004867 10030102 Oedema generalised LLT
    20.1 100000004867 10034611 Peripheral oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) NO (Prematurely Ended) FI (Prematurely Ended) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002622-75 Sponsor Protocol Number: 2013 Start Date*: 2013-05-21
    Sponsor Name:Vibeke Hjortdal
    Full Title: Lymphatic dysfunction as a cause of calcium channel blocker oedema
    Medical condition: Fluid accumulation in the leg associated with calcium channel blocker therapy.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004867 10067033 Drug side effect LLT
    16.0 100000004867 10034570 Peripheral edema LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000681-42 Sponsor Protocol Number: CoRaLa_II Start Date*: 2020-08-24
    Sponsor Name:Justus-Liebig University Gießen
    Full Title: Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion
    Medical condition: Macular edema due to central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10054467 Macular edema LLT
    20.0 100000004853 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003870-41 Sponsor Protocol Number: EC_10/2016 Start Date*: 2017-02-07
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario Príncipe de Asturias
    Full Title: Comparison of treatment of diabetic macular edema with Ozurdex® versus Ozurdex® plus laser in areas of peripheral non-perfusion
    Medical condition: Diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2010-020441-27 Sponsor Protocol Number: CORaLa Start Date*: 2011-02-23
    Sponsor Name:University of Leipzig Ritterstr. 26, 04109 Leipzig
    Full Title: Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion A randomized, controlled interventional phase 2b (proof of concept) study of ...
    Medical condition: macular edema secondary to non-ischemic central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10054467 Macular edema LLT
    14.0 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000385-22 Sponsor Protocol Number: RF-2010-2318561 Start Date*: 2014-10-07
    Sponsor Name:Ospedale San Raffaele di Milano
    Full Title: Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial.
    Medical condition: Retinitis pigmentosa with cystoid macular edema
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004853 10054467 Macular edema LLT
    17.0 10010331 - Congenital, familial and genetic disorders 10038914 Retinitis pigmentosa PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000206-31 Sponsor Protocol Number: C1 1304-01 Start Date*: 2004-06-22
    Sponsor Name:PHARMING TECHNOLOGIES B.V.
    Full Title: A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema
    Medical condition: hereditary angioedema (HAE) treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019860 Hereditary angioedema LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-005721-28 Sponsor Protocol Number: IC4-05682-099 Start Date*: 2007-04-10
    Sponsor Name:Servier s.r.o.
    Full Title: EDET study - Efficacy of Detralex® in Edema Treatment. An open, 6-month, multicentre study.
    Medical condition: Treatment of Chronic Venous Disorder symptoms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047220 Venous (peripheral) insufficiency, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2006-004586-34 Sponsor Protocol Number: CVAA489A2404 Start Date*: 2007-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, multicenter, parallel group study to evaluate the efficacy, tolerability, and safety of treatment with the combination of valsartan/amlodipine 160/5 mg compared to amlod...
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) DE (Completed) SE (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003243-37 Sponsor Protocol Number: Start Date*: 2017-11-02
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10002709 Anterior uveitis LLT
    22.1 10015919 - Eye disorders 10022557 Intermediate uveitis LLT
    20.1 100000004862 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10033687 Panuveitis LLT
    20.1 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2016-000304-29 Sponsor Protocol Number: Start Date*: 2016-04-05
    Sponsor Name:MUST Coordinating Centre, John Hopkins Bloomberg School of Public Health
    Full Title: Periocular and Intravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial
    Medical condition: Uveitic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014995 10002709 Anterior uveitis LLT
    20.0 100000161411 10022557 Intermediate uveitis LLT
    20.0 100000014975 10033687 Panuveitis LLT
    20.0 100000015065 10036370 Posterior uveitis LLT
    20.0 10015919 - Eye disorders 10058202 Cystoid macular oedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000049-19 Sponsor Protocol Number: C1 1310 Start Date*: 2011-04-01
    Sponsor Name:Pharming Technologies B.V.
    Full Title: A Phase IIIb randomized, double-blind, placebo-controlled study with an open-label extension evaluating the efficacy, safety and immunogenicity of recombinant human C1 inhibitor for the treatment o...
    Medical condition: Treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019860 Hereditary angioedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000771-24 Sponsor Protocol Number: CXL-1427-02 Start Date*: 2014-12-22
    Sponsor Name:Cardioxyl Pharmaceuticals, Inc.
    Full Title: A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6-Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients with Systolic Heart Failure
    Medical condition: Heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004849 10024106 Left heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001918-42 Sponsor Protocol Number: 2009-107(Canadian) Start Date*: 2014-01-17
    Sponsor Name:Ottawa Hospital Research Institute
    Full Title: Effect of folic acid supplementation in pregnancy on preeclampsia - Folic Acid Clinical Trial (FACT) A randomized, double-blind, placebo-controlled, Phase III, international multi-centre study of 4...
    Medical condition: pre-eclampsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036485 Pre-eclampsia PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005394-66 Sponsor Protocol Number: ESR-20-21070 Start Date*: 2022-02-21
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA SENESE
    Full Title: Effects of Dapagliflozin on cardiac deformation and clinical outcomes in heart failure with reduced and mildly reduced ejection fraction
    Medical condition: heart failure with left ventricular ejection fraction <50%
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10024102 Left cardiac failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002864-30 Sponsor Protocol Number: NL73019.018.20 Start Date*: 2020-07-29
    Sponsor Name:Amsterdam UMC, location AMC
    Full Title: Sulodexide for chronic heart failure: a proof of concept, randomized, placebo-controlled study
    Medical condition: Chronic heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000369-42 Sponsor Protocol Number: WA43380 Start Date*: 2023-03-15
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: A PHASE III, INTERNATIONAL, MULTICENTER, RANDOMISED OPEN LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB VERSUS MMF IN PATIENTS WITH CHILDHOOD ONSET IDIOPATHIC NEPHROTIC SYNDROME
    Medical condition: Childhood Onset Idiopathic Nephrotic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10029164 Nephrotic syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 31 23:12:12 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA